ADVANCED NON-SMALL CELL LUNG CANCER

This study tests whether adding an experimental drug (fianlimab) to a standard immunotherapy (cemiplimab) works better than the standard drug alone for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. About 850 participants will rece…

This study tests an experimental drug, BAY 2927088, in people with advanced non-small cell lung cancer that has specific changes in the EGFR or HER2 genes. The drug aims to block these abnormal proteins to stop cancer growth. The trial will first find the safest dose and then che…

This study tests a new drug called DS-1062a in 100 people with advanced lung cancer that has not responded to other treatments. The drug is given every three weeks and aims to shrink tumors. Researchers will also study how the drug affects the immune system and look for markers t…

This study tests two experimental drugs (AK112 and AK104) given together, with or without chemotherapy, for people with advanced non-small cell lung cancer that cannot be treated with surgery or radiation. The goal is to see if the combination is safe and helps shrink tumors or s…

This early-stage study tests the safety and best dose of a drug called AZD9291 (osimertinib) combined with either AZD6094 or selumetinib in people with advanced EGFR-mutant lung cancer that has stopped responding to previous treatments. About 344 adults with this specific type of…

This study was designed to test a new combination of drugs for people with advanced non-small cell lung cancer. It aimed to see if adding SHR-A1921, adebrelimab, and SHR-8068, with or without carboplatin, was safe and effective. However, the trial was withdrawn before any partici…

This study tests whether combining immunotherapy drugs can shrink tumors in people with advanced non-small cell lung cancer. About 400 adults with stage IV cancer will receive these combinations. The main goals are to see how many patients respond and to check for side effects.

This early-stage study tests a drug called furmonertinib in 160 people with advanced lung cancer that has certain gene mutations (EGFR or HER2). The goal is to see if the drug is safe and can shrink tumors. Participants have already tried other treatments without success.

This study tests whether adding an experimental drug, BNT116, to the standard immunotherapy cemiplimab works better than cemiplimab alone for people with advanced non-small cell lung cancer. About 51 participants with a specific tumor marker (PD-L1 ≥50%) will receive either the c…

This phase 3 trial tests whether a new drug called AK112 works better than the standard immunotherapy pembrolizumab for people with advanced non-small cell lung cancer that has a specific marker (PD-L1). About 398 participants with stage IIIB/C or IV lung cancer will receive eith…

This study tests an experimental drug (FF-10832) given alone or with pembrolizumab (an immunotherapy) in about 120 adults with advanced lung or bladder cancer that has not responded to standard treatments. The main goals are to check safety and see how long the cancer can be kept…

This study looks back at medical records of about 1,000 people with advanced non-small cell lung cancer who received a combination of the drug cemiplimab and chemotherapy. The goal is to see how safe and effective this treatment is in different groups based on age, sex, race, and…